Abstract
S. L. Durham, C. M. Hare, M. R. Angelastro, J. P. Burkhart, J. R. Koehl, A. L. Marquart, S. Mehdi, N. P. Peet and M. J. Janusz: Pharmacology of N-[4-(4-morpholinylcarbonyl)benzoyl-l-valyl-N-[3,3,4,4,4-pentafluoro-1-(1-methylethyl)-2-oxobutyl]-l-prolinamide (MDL 101,146): A Potent Orally Active Inhibitor of Human Neutrophil Elastase. J. Pharmacol. Exp. Ther. 270(1): 185-191, 1994.
Please note corrections to the article "Pharmacology of N-[4-(4-morpholinylcarbonyl)benzoyl-l-valyl-N-[3,3,4,4,4-pentafluoro-1-(1-methylethyl)-2-oxobutyl]-l-prolinamide (MDL 101,146): A Potent Orally Active Inhibitor of Human Neutrophil Elastase" by Durham et al., volume 270(1): 185-191. Specifically, page 186, Materials and Methods the right column, last line of the first paragraph should have read "substrate were used [S] = 0.05, 0.1, 0.4 or 1.0 mM; [I] = 0, 66.6, 133.3 or 200 nM." Also, page 187, the legend for figure 2 contains an error. MeoSuc-Ala-Ala-Pro-Val-(p-nitroanilide) concentrations were varied from 1.0 to 20 mM should be changed to 0.05 to 1 mM. The authors regret these errors.
- 1994 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
